Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | PPM1A | P35813 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13659623 | 0.81 | CHEK1 (0.51) | CHEK1LMNA | |
| SCHEMBL4297821 | 0.74 | CHEK1 (0.45) | CHEK1MEN1KMT2ARXFP1KDM4E | |
| SCHEMBL9475347 | 0.72 | CHEK1 (0.50) | CHEK1MEN1KMT2ARXFP1ERN1 | |
| SCHEMBL4296233 | 0.71 | CHEK1 (0.47) | CHEK1MEN1KMT2ARXFP1KDM4E | |
| SCHEMBL4300826 | 0.69 | — | — | |
| SCHEMBL23557597 | 0.67 | GPR84 (0.33) | — | |
| SCHEMBL13659562 | 0.66 | CHEK1 (0.36) | CHEK1MEN1KMT2A | |
| SCHEMBL31556379 | 0.66 | CYP2A6 (0.46) | MEN1KMT2AERN1KDM4ELMNA | |
| SCHEMBL7002379 | 0.66 | CYP2A6 (0.46) | MEN1KMT2AERN1KDM4ELMNA | |
| SCHEMBL1536308 | 0.66 | CYP2A6 (0.46) | MEN1KMT2AERN1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| WO-2007008502-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, CDKN1A | CHEK1 1/4885MEN1 1110/4885KMT2A 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.